Therapeutic approaches for CCNE1-amplified HR-proficient ovarian cancer.

被引：0
|
作者：
Bai, Shoumei [1 ]
Buckanovich, Ronald J. [1 ]
机构：
[1] Univ Pittsburgh, Magee Womens Res Inst, Pittsburgh, PA USA
来源：
CANCER RESEARCH | 2021年 / 81卷 / 13期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2060
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Targeting Therapeutic Resistance and Multinucleate Giant Cells in CCNE1-Amplified HR-Proficient Ovarian Cancer
    Bai, Shoumei
    Taylor, Sarah E.
    Jamalruddin, Mohd Azrin
    McGonigal, Stacy
    Grimley, Edward
    Yang, Dongli
    Bernstein, Kara A.
    Buckanovich, Ronald J.
    MOLECULAR CANCER THERAPEUTICS, 2022, 21 (09) : 1473 - 1484
  • [2] Molecular landscape and clinical implication of CCNE1-amplified esophagogastric cancer.
    Moy, Ryan H.
    Wu, Sharon
    Xiu, Joanne
    Walker, Phillip
    Korn, Wolfgang Michael
    Lou, Emil
    Shields, Anthony Frank
    Goel, Sanjay
    Saeed, Anwaar
    Bass, Adam Joel
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 440 - 440
  • [3] Targeting chemo-resistance in CCNE1-amplified ovarian cancer
    Taylor-Harding, Barbie
    Agadjanian, Hasmik
    Aspuria, Paul Joseph
    Mizuno, Takako
    Cheon, Dong-Joo
    Orsulic, Sandra
    Karlan, Beth
    Walsh, Christine
    Wiedemeyer, Wolf Ruprecht
    CLINICAL CANCER RESEARCH, 2013, 19
  • [4] Molecular Landscape and Clinical Implication of CCNE1-amplified Esophagogastric Cancer
    Rustgi, Naryan
    Wu, Sharon
    Samec, Timothy
    Walker, Phillip
    Xiu, Joanne
    Lou, Emil
    Goel, Sanjay
    Saeed, Anwaar
    Moy, Ryan H.
    CANCER RESEARCH COMMUNICATIONS, 2024, 4 (06): : 1399 - 1409
  • [5] Resistance to CDK2 Inhibitors Is Associated with Selection of Polyploid Cells in CCNE1-Amplified Ovarian Cancer
    Etemadmoghadam, Dariush
    Au-Yeung, George
    Wall, Meaghan
    Mitchell, Chris
    Kansara, Maya
    Loehrer, Elizabeth
    Batzios, Crisoula
    George, Joshy
    Ftouni, Sarah
    Weir, Barbara A.
    Carter, Scott
    Gresshoff, Irma
    Mileshkin, Linda
    Rischin, Danny
    Hahn, William C.
    Waring, Paul M.
    Getz, Gad
    Cullinane, Carleen
    Campbell, Lynda J.
    Bowtell, David D.
    CLINICAL CANCER RESEARCH, 2013, 19 (21) : 5960 - 5971
  • [6] Adavosertib Is Safe and Efficacious in CCNE1-Amplified Solid Tumors
    de Ruijiter, L. Kist
    van de Donk, P. P.
    Hooiveld-Noeken, J. S.
    Giesen, D.
    Elias, S. G.
    Hooge, M. N. Lub-de
    CANCER DISCOVERY, 2023, 13 (02) : 257 - 257
  • [7] Targeting the metabolic-epigenetic axis to sensitize HR-proficient ovarian cancer to PARP inhibitors
    Dahl, Erika S.
    Leon, Kelly E.
    Chen, Chi-Wei
    Jia, Qingyuan
    Buj, Raquel
    Snyder, Nathaniel W.
    Aird, Katherine M.
    CANCER RESEARCH, 2020, 80 (16)
  • [8] CDK2 regulates collapsed replication fork repair in CCNE1-amplified ovarian cancer cells via homologous recombination
    Brown, Victoria E.
    Moore, Sydney L.
    Chen, Maxine
    House, Nealia
    Ramsden, Philip
    Wu, Hsin-Jung
    Ribich, Scott
    Grassian, Alexandra R.
    Choi, Yoon Jong
    NAR CANCER, 2023, 5 (03):
  • [9] Functional Homologous Recombination (HR) Screening Shows the Majority of BRCA1/2-Mutant Breast and Ovarian Cancer Cell Lines Are HR-Proficient
    Meijer, Titia G.
    Martens, John W. M.
    Prager-van der Smissen, Wendy J. C.
    Verkaik, Nicole S.
    Beaufort, Corine M.
    van Herk, Stanley
    Robert-Finestra, Teresa
    Hoogenboezem, Remco M.
    Ruigrok-Ritstier, Kirsten
    Paul, Maarten W.
    Gribnau, Joost
    Bindels, Eric M. J.
    Kanaar, Roland
    Jager, Agnes
    van Gent, Dik C.
    Hollestelle, Antoinette
    CANCERS, 2024, 16 (04)
  • [10] Therapeutic approaches for ARID1A-mutated ovarian cancer.
    Zhang, Rugang
    CLINICAL CANCER RESEARCH, 2020, 26 (13) : 26 - 26
12345